Compare Nutanix Inc (NTNX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs GeneDx Holdings Corp — how do they compare? Nutanix Inc trades at $74.59 (market cap $19.78B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Nutanix Inc is far larger — about 9.8× GeneDx Holdings Corp's market cap, and Nutanix Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and GeneDx Holdings Corp for 19 Days on average.
| NTNX | WGS | |
|---|---|---|
Market Cap | $19.78B | $2.02B |
Volume | 1,717,619 | 734,640 |
Sector | Technology | Health |
52-Week High | $73.42 | $167.51 |
52-Week Low | $34.41 | $34.51 |
Typical Hold Time | 17 Days | 19 Days |
Enterprise Value | $18.94B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $73.98, up 0.76% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust profitability with a net income margin of 52.81% for 2026 and is recognized as a leader in multiple Gartner Magic Quadrant reports, highlighting its competitive strength in hybrid cloud infrastructure.
The outlook is positive with analyst consensus favoring a buy rating and a $76.11 price target, though risks include high valuation multiples like a 46.22 EV/EBITDA and negative ROE. Revenue growth and external storage expansion present opportunities, but investors should monitor execution against guidance and market volatility.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
